Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$726.35
-2.2%
$743.84
$623.78
$942.35
$703.13B0.475.28 million shs3.95 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$55.15
-1.8%
$59.46
$45.05
$138.22
$250.67B0.6614.63 million shs15.49 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.86
+1.3%
$24.85
$20.92
$30.43
$139.52B0.5534.76 million shs34.59 million shs
Roche Holding AG stock logo
RHHBY
Roche
$43.00
+0.6%
$40.21
$34.10
$44.31
$271.96B0.471.46 million shs565,016 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.98
+1.7%
$31.22
$18.92
$81.73
$3.03B0.739.57 million shs5.24 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.14%-0.83%-2.66%-5.67%-23.24%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.78%-2.40%+21.71%-26.18%-59.00%
Pfizer Inc. stock logo
PFE
Pfizer
+1.43%+0.47%+3.79%+6.40%-12.42%
Roche Holding AG stock logo
RHHBY
Roche
+0.61%+5.47%+12.10%+5.24%+5.01%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.70%-0.26%-15.37%-3.05%-53.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$726.35
-2.2%
$743.84
$623.78
$942.35
$703.13B0.475.28 million shs3.95 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$55.15
-1.8%
$59.46
$45.05
$138.22
$250.67B0.6614.63 million shs15.49 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.86
+1.3%
$24.85
$20.92
$30.43
$139.52B0.5534.76 million shs34.59 million shs
Roche Holding AG stock logo
RHHBY
Roche
$43.00
+0.6%
$40.21
$34.10
$44.31
$271.96B0.471.46 million shs565,016 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.98
+1.7%
$31.22
$18.92
$81.73
$3.03B0.739.57 million shs5.24 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.14%-0.83%-2.66%-5.67%-23.24%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.78%-2.40%+21.71%-26.18%-59.00%
Pfizer Inc. stock logo
PFE
Pfizer
+1.43%+0.47%+3.79%+6.40%-12.42%
Roche Holding AG stock logo
RHHBY
Roche
+0.61%+5.47%+12.10%+5.24%+5.01%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.70%-0.26%-15.37%-3.05%-53.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.70
Moderate Buy$950.1730.81% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$81.0046.88% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.39
Hold$28.1213.13% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.57
Moderate BuyN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$86.92222.18% Upside

Current Analyst Ratings Breakdown

Latest VKTX, PFE, RHHBY, LLY, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeReduceHold$675.00 ➝ $700.00
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate SellHold
8/22/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/20/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHoldStrong Sell
8/19/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$105.00 ➝ $70.00
8/19/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$102.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformNeutral$700.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/14/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DZ Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/13/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$975.00 ➝ $825.00
8/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperformNeutral
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$53.26B12.91$13.92 per share52.19$15.03 per share48.33
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B5.85$3.83 per share14.39$4.66 per share11.83
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.22$4.42 per share5.62$15.62 per share1.59
Roche Holding AG stock logo
RHHBY
Roche
$68.73B3.98$3.32 per share12.94$6.46 per share6.66
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3047.4723.341.0325.91%92.72%16.89%10/29/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.6415.1511.831.9535.60%78.64%24.51%11/5/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.228.200.8716.84%21.42%9.12%11/4/2025 (Estimated)
Roche Holding AG stock logo
RHHBY
Roche
$9.40BN/A0.0014.332.35N/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)

Latest VKTX, PFE, RHHBY, LLY, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/6/2025Q2 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44-$0.58-$0.14-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.83%N/A39.22%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.49%N/A22.53%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.92%N/A91.49%16 Years
Roche Holding AG stock logo
RHHBY
Roche
$0.872.02%N/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VKTX, PFE, RHHBY, LLY, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
8/6/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.41192.4%8/18/20258/18/20258/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.52
0.78
0.56
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85
Roche Holding AG stock logo
RHHBY
Roche
0.85
1.48
1.20
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
25.86
25.86

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Roche Holding AG stock logo
RHHBY
Roche
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Roche Holding AG stock logo
RHHBY
Roche
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.23 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,2496.36 billionN/ANot Optionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.45 million107.84 millionOptionable

Recent News About These Companies

Braidwell LP Trims Position in Viking Therapeutics, Inc. $VKTX
Brokers Issue Forecasts for VKTX Q3 Earnings
Q3 Earnings Forecast for VKTX Issued By B. Riley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$726.35 -16.56 (-2.23%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$725.84 -0.52 (-0.07%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$55.15 -0.99 (-1.77%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$55.20 +0.05 (+0.10%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$24.86 +0.32 (+1.28%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$24.85 0.00 (-0.02%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Roche stock logo

Roche OTCMKTS:RHHBY

$43.00 +0.26 (+0.61%)
As of 09/5/2025 04:00 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$26.98 +0.45 (+1.70%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$26.82 -0.16 (-0.58%)
As of 09/5/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.